Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Thrives Through Knoll Transition; Will Other Firms Follow In 2002?

Executive Summary

Abbott's strong showing on Wall Street in 2001 may be a hopeful sign for the growing group of pharmaceutical companies looking at 2002 as a transition year

You may also be interested in...



Schering Sees Growth Opportunity For Organon Products In The U.S. – Hassan

Schering-Plough sees significant growth potential for Organon's products that currently are marketed in the U.S., CEO Fred Hassan said March 20

Schering Sees Growth Opportunity For Organon Products In The U.S. – Hassan

Schering-Plough sees significant growth potential for Organon's products that currently are marketed in the U.S., CEO Fred Hassan said March 20

Cardinal Manufactures 10% Gain In 1Q: Rx Stocks Stay Out Of Favor

Cardinal's expanding manufacturing capacity is enhancing its image with investors who are attracted to the pharmaceutical sector but wary of the risks of drug development

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel